Clinical Trial News and Research

RSS

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Researchers evaluate new treatment for coronary heart disease

Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment.

13 Apr 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.

12 Apr 2010

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.

12 Apr 2010

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

GenVec, Inc. announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.

12 Apr 2010

BioClinica to showcase expanded suite of services at upcoming global industry conferences

BioClinica, Inc., a leading provider of clinical trial management services will participate in, and present at, key industry conferences during April and May. Principal members of the BioClinica team will participate as expert panelists as well as demonstrate the value of the Company's expanded suite of services at these conferences.

From Clario 12 Apr 2010

Internet-based CBT as effective as group therapy for treating panic disorder

Cognitive behaviour therapy (CBT) via the internet is just as effective in treating panic disorder (recurring panic attacks) as traditional group-based CBT. It is also efficacious in the treatment of mild and moderate depression. This according to a new doctoral thesis soon to be presented at the Swedish medical university Karolinska Institutet.

12 Apr 2010

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Optimer Pharmaceuticals, Inc. announced that the top-line results from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection were presented today at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria.

12 Apr 2010

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.

12 Apr 2010

New TIVR telephone system to teach pain management skills to patients with arthritis

Joan Broderick, Ph.D., Research Associate Professor, Department of Psychiatry and Behavioral Sciences at Stony Brook University, has received a $606,000 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

12 Apr 2010

FDA grants 510(K) clearance to market Vitala Continence Control Device

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today that the U.S. Food and Drug Administration has granted 510(K) clearance to market Vitala, an exceptionally innovative, non-intrusive ostomy continence control device, for people with an end colostomy.

9 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Catalyst Pharmaceutical Partners, Inc. today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence"

9 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.

9 Apr 2010

PAREXEL International experts to present key industry topics during conference in Orlando

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will present key industry topics during the 19th Annual Partnerships in Clinical Trials Conference, to be held April 12 – 14, 2010 in Orlando, Florida.

From Parexel 9 Apr 2010

World's largest autism science and advocacy organization awards 16 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 16 new research grants totaling $5,223,743 over the next three years.

9 Apr 2010

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

9 Apr 2010

Idaho man fourth in country to receive Levacor- VAD implant

After receiving only the fourth U.S. implant of a new-generation, Utah-made ventricular assist (VAD ) device, an Idaho man with heart failure is looking forward to resuming an active life following an operation on March 17 at University of Utah Hospital.

9 Apr 2010

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

9 Apr 2010

Clinical Trial News and Research

Gilead Sciences doses first patient in Quad Phase III clinical program

Researchers evaluate new treatment for coronary heart disease

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

BioClinica to showcase expanded suite of services at upcoming global industry conferences

Internet-based CBT as effective as group therapy for treating panic disorder

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

New TIVR telephone system to teach pain management skills to patients with arthritis

FDA grants 510(K) clearance to market Vitala Continence Control Device

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Tβ4 therapy for ocular disorders closer to reality

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

PAREXEL International experts to present key industry topics during conference in Orlando

World's largest autism science and advocacy organization awards 16 new research grants

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

Idaho man fourth in country to receive Levacor- VAD implant

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery